Levodopa/Carbidopa (LD/CD) — Competitive Intelligence Brief

Levodopa/Carbidopa (LD/CD) (Levodopa/Carbidopa (LD/CD)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor with peripheral decarboxylase inhibitor. Area: Neurology.

phase 3 Dopamine precursor with peripheral decarboxylase inhibitor Dopamine pathway; aromatic L-amino acid decarboxylase (carbidopa component) Neurology Small molecule

Target snapshot

Levodopa/Carbidopa (LD/CD) (Levodopa/Carbidopa (LD/CD)) — AbbVie. Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion in the periphery, allowing more levodopa to reach the central nervous system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levodopa/Carbidopa (LD/CD) TARGET	Levodopa/Carbidopa (LD/CD)	AbbVie	phase 3	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (carbidopa component)
Levodopa Benserazide Madopar	Levodopa Benserazide Madopar	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide)
Sinemet (comparator)	Sinemet (comparator)	XenoPort, Inc.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic L-amino acid decarboxylase (AADC); dopaminergic system
Levodopa Benserazide Teva Italia	Levodopa Benserazide Teva Italia	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (inhibited by benserazide); dopamine receptors (target of levodopa-derived dopamine)
controlled-release levodopa / carbidopa	controlled-release levodopa / carbidopa	Pfizer	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
Levodopa + benserazide	Levodopa + benserazide	University of Buenos Aires	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition)
Levodopa / Carbidopa	Levodopa / Carbidopa	Ross D. Zafonte, MD	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor with peripheral decarboxylase inhibitor class)

1. Bial - Portela C S.A. · 2 drugs in this class
2. IRCCS San Raffaele Roma · 2 drugs in this class
3. NeuroDerm Ltd. · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Ross D. Zafonte, MD · 1 drug in this class
6. University of Buenos Aires · 1 drug in this class
7. AbbVie · 1 drug in this class
8. XenoPort, Inc. · 1 drug in this class
9. Intec Pharma Ltd. · 1 drug in this class